View Future GrowthRidgetech 과거 순이익 실적과거 기준 점검 0/6Ridgetech은 연평균 6.6%의 비율로 수입이 증가해 온 반면, Consumer Retailing 산업은 연평균 12.9%의 비율로 증가했습니다. 매출은 연평균 1.8%의 비율로 감소했습니다.핵심 정보6.63%순이익 성장률78.04%주당순이익(EPS) 성장률Consumer Retailing 산업 성장률10.91%매출 성장률-1.84%자기자본이익률-6.72%순이익률-1.67%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).Reported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updatesNew Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.공시 • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingBuy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.공시 • Nov 13Ridgetech, Inc., Annual General Meeting, Dec 12, 2025Ridgetech, Inc., Annual General Meeting, Dec 12, 2025, at 09:00 China Standard Time. Location: 5th floor, building 6, no. 100, 18th street, baiyang sub-district, qiantang district, zhejiang province, p. r. china, 310008., hangzhou China공시 • Oct 23Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stock공시 • Sep 26Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common StockReported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$5.80m market cap).공시 • Feb 07China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025, at 10:00 China Standard Time. Location: located at 4th floor, building 5, renxin yaju, gon, gong shu district, zhejiang, hangzhou city, ChinaNew Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap).Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).분석 기사 • Oct 30China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks ReasonableChina Jo-Jo Drugstores, Inc. ( NASDAQ:CJJD ) shareholders are no doubt pleased to see that the share price has bounced...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (295% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.8m market cap).New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$9.72m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).공시 • Jun 01China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of DirectorsChina Jo-Jo Drugstores, Inc. announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors (the "Board") due to personal reasons, effective on May 31, 2024. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company's business operations, financial reporting or controls, policies or practices.공시 • Apr 30China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 900,000 Price\Range: $1.7 Transaction Features: Registered Direct OfferingNew Risk • Apr 01New major risk - Revenue and earnings growthRevenue has declined by 9.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.5% over the past year. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (US$5.30m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Jan 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$7.47m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Share price has been volatile over the past 3 months (12% average weekly change).공시 • Nov 15China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023, at 21:00 US Eastern Standard Time. Location: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou City, Zhejiang Province, P. R. China, 310008 Zhejiang China Agenda: To elect six directors to serve until the next Annual Meeting or until their successors are duly elected and qualified;to ratify the appointment of YCM CPA, Inc. as the Company's independent registered public accounting firm for the fiscal year ending March 31,2024; to approve by ordinary resolution the proposed reverse stock split and consolidation of the Company's issued and outstanding ordinary shares;to approve by ordinary resolution the increase of authorized share capital;to approve by special resolution the Amendment of the Memorandum and Articles of Association of the Company to effect the reverse stock split and consolidation of the Company's issued and outstanding ordinary shares, and the increase of authorized share capital;to approve the Third Amended and Restated 2010 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.89m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.89m market cap).공시 • Jun 18China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn June 16, 2023, China Jo-Jo Drugstores, Inc. announced that on June 15, 2023, the company has received a notification letter from Nasdaq Listing Qualifications Department (‘Nasdaq’) notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) (‘Nasdaq Listing Rule’), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of USD 1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least USD 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. The company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards the end of the first compliance period, the company's Board of Directors will consider options that may be available to achieve compliance.Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Jul 28China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39MChina Jo - Jo Drugstores press release (NASDAQ:CJJD): FY GAAP EPS of -$0.92. Revenue of $164.39M (+23.5% Y/Y). Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year. Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year. Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.공시 • Apr 28China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced on April 27, 2022 that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on April 25, 2022, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and the matter is closed. On July 26, 2021, the Company was first notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given its first 180-day extension, or until January 24, 2022 to regain compliance. On January 25, 2022, the Company received a second 180-day extension from Nasdaq or until July 25, 2022 to regain compliance. Effective April 7, 2022, the Company effected a 1-for-12 reverse stock split. The letter dated April 25, 2022 the Company received from Nasdaq noted that as of April 22, 2022, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from April 7, 2022 through April 22, 2022. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is closed.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 27China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced that on January 25, 2022, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until July 25, 2022 to regain compliance. If at any time before July 25, 2022, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on July 26, 2021, and was given until January 24, 2022 to regain compliance.Reported Earnings • Jan 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up US$1.73m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 01Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$133.1m (up 14% from FY 2020). Net loss: US$8.12m (loss widened 40% from FY 2020). Like-for-like sales growth: Down 1.3% vs FY 2020 Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 05New 90-day low: US$0.98The company is down 11% from its price of US$1.10 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period.Reported Earnings • Feb 14Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$35.5m (up 6.5% from 3Q 2020). Net loss: US$6.26m (down US$6.79m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.분석 기사 • Feb 09China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five YearsIdeally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...Is New 90 Day High Low • Feb 06New 90-day high: US$1.24The company is up 16% from its price of US$1.07 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: US$1.15The company is up 22% from its price of US$0.94 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.공시 • Dec 24China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc., on December 23, 2020 announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. As previously disclosed, on October 16, 2020, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Nasdaq Listing Rules. On December 17, 2020, Nasdaq provided confirmation to the Company that for the last 20 consecutive business days, from November 18 to December 14, 2020, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).Reported Earnings • Nov 18Second quarter 2021 earnings released: US$0.039 loss per shareThe company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: US$30.8m (up 8.8% from 2Q 2020). Net loss: US$1.49m (loss widened 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 31New 90-day low: US$0.90The company is down 25% from its price of US$1.20 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: US$0.91The company is down 32% from its price of US$1.35 on 17 July 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 10.0% over the same period.매출 및 비용 세부 내역Ridgetech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:RDGT 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 25120-25030 Jun 25120-25031 Mar 25120-15030 Sep 24147-636030 Jun 24151-535031 Mar 24124-14031 Dec 23155-1344030 Sep 23155-2153030 Jun 23152-2154031 Mar 23120-1617031 Dec 22154-1248030 Sep 22159-441030 Jun 22162-340031 Mar 22164-339031 Dec 21157-234030 Sep 21150-737030 Jun 21141-837031 Mar 21133-838031 Dec 20128-1139030 Sep 20126-432030 Jun 20123-431031 Mar 20117-632031 Dec 19113027030 Sep 19111-229030 Jun 19110-229031 Mar 19108-126031 Dec 18105-1739030 Sep 18101-1737030 Jun 1897-1637031 Mar 1896-1737031 Dec 1792-927030 Sep 1786-824030 Jun 1782-722031 Mar 1781-621031 Dec 1682018030 Sep 1686018030 Jun 1689018031 Mar 1689018031 Dec 1589116030 Sep 1586213030 Jun 15821120양질의 수익: RDGT 은(는) 현재 수익성이 없습니다.이익 마진 증가: RDGT는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RDGT는 수익성이 없지만 지난 5년 동안 연평균 6.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RDGT의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RDGT은 수익성이 없어 지난 해 수익 성장률을 Consumer Retailing 업계(13%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RDGT는 현재 수익성이 없으므로 자본 수익률이 음수(-6.72%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-retailing 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 02:01종가2026/05/22 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ridgetech, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).
Reported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).
Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).
Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).
Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).
Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).
Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).
New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).
Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
공시 • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Buy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
공시 • Nov 13Ridgetech, Inc., Annual General Meeting, Dec 12, 2025Ridgetech, Inc., Annual General Meeting, Dec 12, 2025, at 09:00 China Standard Time. Location: 5th floor, building 6, no. 100, 18th street, baiyang sub-district, qiantang district, zhejiang province, p. r. china, 310008., hangzhou China
공시 • Oct 23Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stock
공시 • Sep 26Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stock
Reported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).
New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$5.80m market cap).
공시 • Feb 07China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025, at 10:00 China Standard Time. Location: located at 4th floor, building 5, renxin yaju, gon, gong shu district, zhejiang, hangzhou city, China
New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap).
Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).
분석 기사 • Oct 30China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks ReasonableChina Jo-Jo Drugstores, Inc. ( NASDAQ:CJJD ) shareholders are no doubt pleased to see that the share price has bounced...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (295% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.8m market cap).
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$9.72m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).
공시 • Jun 01China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of DirectorsChina Jo-Jo Drugstores, Inc. announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors (the "Board") due to personal reasons, effective on May 31, 2024. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company's business operations, financial reporting or controls, policies or practices.
공시 • Apr 30China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 900,000 Price\Range: $1.7 Transaction Features: Registered Direct Offering
New Risk • Apr 01New major risk - Revenue and earnings growthRevenue has declined by 9.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.5% over the past year. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (US$5.30m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Jan 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$7.47m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Share price has been volatile over the past 3 months (12% average weekly change).
공시 • Nov 15China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023, at 21:00 US Eastern Standard Time. Location: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou City, Zhejiang Province, P. R. China, 310008 Zhejiang China Agenda: To elect six directors to serve until the next Annual Meeting or until their successors are duly elected and qualified;to ratify the appointment of YCM CPA, Inc. as the Company's independent registered public accounting firm for the fiscal year ending March 31,2024; to approve by ordinary resolution the proposed reverse stock split and consolidation of the Company's issued and outstanding ordinary shares;to approve by ordinary resolution the increase of authorized share capital;to approve by special resolution the Amendment of the Memorandum and Articles of Association of the Company to effect the reverse stock split and consolidation of the Company's issued and outstanding ordinary shares, and the increase of authorized share capital;to approve the Third Amended and Restated 2010 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.89m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.89m market cap).
공시 • Jun 18China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn June 16, 2023, China Jo-Jo Drugstores, Inc. announced that on June 15, 2023, the company has received a notification letter from Nasdaq Listing Qualifications Department (‘Nasdaq’) notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) (‘Nasdaq Listing Rule’), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of USD 1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least USD 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. The company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards the end of the first compliance period, the company's Board of Directors will consider options that may be available to achieve compliance.
Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Jul 28China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39MChina Jo - Jo Drugstores press release (NASDAQ:CJJD): FY GAAP EPS of -$0.92. Revenue of $164.39M (+23.5% Y/Y). Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year. Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year. Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.
공시 • Apr 28China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced on April 27, 2022 that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on April 25, 2022, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and the matter is closed. On July 26, 2021, the Company was first notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given its first 180-day extension, or until January 24, 2022 to regain compliance. On January 25, 2022, the Company received a second 180-day extension from Nasdaq or until July 25, 2022 to regain compliance. Effective April 7, 2022, the Company effected a 1-for-12 reverse stock split. The letter dated April 25, 2022 the Company received from Nasdaq noted that as of April 22, 2022, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from April 7, 2022 through April 22, 2022. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is closed.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 27China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced that on January 25, 2022, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until July 25, 2022 to regain compliance. If at any time before July 25, 2022, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on July 26, 2021, and was given until January 24, 2022 to regain compliance.
Reported Earnings • Jan 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up US$1.73m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 01Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$133.1m (up 14% from FY 2020). Net loss: US$8.12m (loss widened 40% from FY 2020). Like-for-like sales growth: Down 1.3% vs FY 2020 Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 05New 90-day low: US$0.98The company is down 11% from its price of US$1.10 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period.
Reported Earnings • Feb 14Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$35.5m (up 6.5% from 3Q 2020). Net loss: US$6.26m (down US$6.79m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
분석 기사 • Feb 09China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five YearsIdeally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
Is New 90 Day High Low • Feb 06New 90-day high: US$1.24The company is up 16% from its price of US$1.07 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: US$1.15The company is up 22% from its price of US$0.94 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.
공시 • Dec 24China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc., on December 23, 2020 announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. As previously disclosed, on October 16, 2020, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Nasdaq Listing Rules. On December 17, 2020, Nasdaq provided confirmation to the Company that for the last 20 consecutive business days, from November 18 to December 14, 2020, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).
Reported Earnings • Nov 18Second quarter 2021 earnings released: US$0.039 loss per shareThe company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: US$30.8m (up 8.8% from 2Q 2020). Net loss: US$1.49m (loss widened 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 31New 90-day low: US$0.90The company is down 25% from its price of US$1.20 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: US$0.91The company is down 32% from its price of US$1.35 on 17 July 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 10.0% over the same period.